358 related articles for article (PubMed ID: 33261056)
1. Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab.
Herbreteau G; Langlais A; Greillier L; Audigier-Valette C; Uwer L; Hureaux J; Moro-Sibilot D; Guisier F; Carmier D; Madelaine J; Otto J; Souquet PJ; Gounant V; Merle P; Molinier O; Renault A; Rabeau A; Morin F; Denis MG; Pujol JL
J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261056
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
3. Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
Zhang J; Zhou N; Deng H; Chen X; Chen Q; Wang Q; Sun L; Wen Y; Cao X; Luo Z; Zhang J; Zhu W; Guo L
Lung Cancer; 2023 Apr; 178():11-19. PubMed ID: 36758321
[TBL] [Abstract][Full Text] [Related]
4. Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease.
Iams WT; Kopparapu PR; Yan Y; Muterspaugh A; Zhao Z; Chen H; Cann C; York S; Horn L; Ancell K; Wyman K; Bertucci C; Shaffer T; Hodsdon LA; Garg K; Hosseini SA; Lim LP; Lovly CM
JTO Clin Res Rep; 2020 Jun; 1(2):100024. PubMed ID: 34589931
[TBL] [Abstract][Full Text] [Related]
5. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
7. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival.
Botrus G; Uson Junior PLS; Raman P; Kaufman AE; Kosiorek H; Yin J; Fu Y; Majeed U; Sonbol MB; Ahn DH; Chang IW; Drusbosky LM; Dada H; Starr J; Borad M; Mody K; Bekaii-Saab TS
Front Oncol; 2021; 11():794009. PubMed ID: 35083150
[TBL] [Abstract][Full Text] [Related]
8.
Francis JH; Gobin YP; Brannon AR; Swartzwelder CE; Berger MF; Mandelker DL; Walsh MF; Dunkel IJ; Abramson DH
Ophthalmol Sci; 2021 Sep; 1(3):100042. PubMed ID: 36247821
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Wislez M; Domblides C; Greillier L; Mazières J; Monnet I; Kiakouama-Maleka L; Quantin X; Spano JP; Ricordel C; Fraisse P; Janicot H; Audigier-Valette C; Amour E; Langlais A; Rabbe N; Makinson A; Cadranel J; Laurent-Puig P; Lavolé A; Blons H
Lung Cancer; 2021 Jul; 157():124-130. PubMed ID: 34016488
[TBL] [Abstract][Full Text] [Related]
10. [
Xu HQ; Song LJ; Ding CY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer.
van Velzen MJM; Creemers A; van den Ende T; Schokker S; Krausz S; Reinten RJ; Dijk F; van Noesel CJM; Halfwerk H; Meijer SL; Mearadji B; Derks S; Bijlsma MF; van Laarhoven HWM
Gastric Cancer; 2022 Sep; 25(5):906-915. PubMed ID: 35763187
[TBL] [Abstract][Full Text] [Related]
12. ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Zou W; Yaung SJ; Fuhlbrück F; Ballinger M; Peters E; Palma JF; Shames DS; Gandara D; Jiang Y; Patil NS
JCO Precis Oncol; 2021 Nov; 5():827-838. PubMed ID: 34994614
[TBL] [Abstract][Full Text] [Related]
13. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
15. The Landscape of Actionable Genomic Alterations by Next-Generation Sequencing in Tumor Tissue Versus Circulating Tumor DNA in Chinese Patients With Non-Small Cell Lung Cancer.
Cai J; Jiang H; Li S; Yan X; Wang M; Li N; Zhu C; Dong H; Wang D; Xu Y; Xie H; Wu S; Lou J; Zhao J; Li Q
Front Oncol; 2021; 11():751106. PubMed ID: 35273907
[TBL] [Abstract][Full Text] [Related]
16. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
18. ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study.
Gerard L; Garcia J; Gauthier A; Lopez J; Durand A; Hervieu V; Lemelin A; Chardon L; Landel V; Gibert B; Lombard-Bohas C; Payen L; Walter T
Neuroendocrinology; 2021; 111(10):951-964. PubMed ID: 33099543
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
20. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance.
O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB
Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
